Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  Swiss Exchange  >  Roche Holding Ltd.    ROG   CH0012032048


News SummaryMost relevantAll newsOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Novartis raises full-year targets, aims to settle U.S. lawsuit

share with twitter share with LinkedIn share with facebook
share via e-mail
07/18/2019 | 06:10am EDT
FILE PHOTO: Switzerland's national flag flies in front of the logo of Swiss drugmaker Novartis in Basel

ZURICH (Reuters) - Novartis boss Vas Narasimhan raised full-year targets on Thursday and announced that $700 million (£561.7 million) has been set aside in the hope of settling a decade-old lawsuit alleging that the Swiss drugmaker bribed U.S. doctors.

ZURICH (Reuters) - Novartis boss Vas Narasimhan raised full-year targets on Thursday and announced that $700 million (£561.7 million) has been set aside in the hope of settling a decade-old lawsuit alleging that the Swiss drugmaker bribed U.S. doctors.

Shares in the company rose about 5% to their highest since 2015, buoyed by second-quarter results, earnings guidance and the prospect of avoiding trial in a case that began in 2011 as a whistleblower lawsuit filed by a former employee.

The lawsuit, since joined by the U.S. government, contends that Novartis paid millions of dollars in kickbacks to doctors so they would prescribe its products, including hypertension treatment Lotrel and diabetes drug Starlix.

A May trial was cancelled as talks began in an effort to settle a case that could result in a multibillion-dollar hit if the company lost in court.

"We're working in settlement discussions to resolve the civil suit," Chief Executive Narasimhan told reporters. "We've provisioned approximately $700 million."

A string of alleged ethical shortcomings over two decades have already cost Novartis $1 billion in the United States, China and Korea while damaging a reputation that Narasimhan has made a priority of improving since becoming CEO in 2018.

U.S. prosecutors have declined to comment.


Novartis on Thursday reported a 20% jump in second-quarter core operating income to $3.6 billion with sales up 8% at $11.8 billion, beating an $11.5 billion forecast in a Refinitiv poll.

The company now expects 2019 core operating income to grow at low double-digit to mid-teen percentages, Narasimhan said, up from a previous target in the high single digits.

Sales growth is expected in the mid-to-high single digits, against previous guidance for a mid-single-digit percentage.

Its Entresto heart failure medicine registered an 81% leap in second-quarter sales to $421 million. Inflammation drug Cosentyx, the company' top seller, reached $858 million, up 25%.

The company's Innovative Medicines business achieved a core operating margin of 35.4%, hitting Narasimhan's mid-term target ahead of schedule.

"The margin for the quarter was particularly convincing for Innovative Medicines," said Vontobel analyst Stefan Schneider. "The raised FY guidance does not look ambitious."

Novartis also revised full-year sales forecasts for its Sandoz business, lifting them broadly in line with last year or possible low-single-digit growth as its copies of Roche's Mabthera, AbbVie Humira and Amgen and Pfizer Enbrel capture market share in Europe.


Narasimhan called the result a positive surprise, adding that a revamp of Sandoz to make it an autonomous division within Novartis, which some analysts speculate could herald an eventual sale, remains "a couple-of-years journey".

He also highlighted the second-quarter launch of gene therapy Zolgensma, the world's most expensive drug at $2.1 million per patient, for deadly spinal muscular atrophy (SMA), saying he was pleased with its progress.

Payers are grappling with its high one-off cost, but Narasimhan on Thursday said that children under two -- the initial patient group for which U.S. regulators approved the medicine -- have access when physicians request it.

"We're on track and fully in line with what we expected," Narasimhan said.

(Reporting by John Miller; Editing by David Goodman)

By John Miller

Stocks mentioned in the article
ChangeLast1st jan.
ABBVIE 3.31% 66.56 Delayed Quote.-27.80%
ALCON 2.01% 60.4 Delayed Quote.0.00%
AMGEN 0.97% 206 Delayed Quote.5.82%
NOVARTIS 0.42% 87.89 Delayed Quote.17.81%
PFIZER 1.53% 35.18 Delayed Quote.-19.40%
ROCHE HOLDING LTD. 0.55% 274.7 Delayed Quote.12.24%
share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on ROCHE HOLDING LTD.
08/16FDA approves Roche's RozlytrekTM (entrectinib) for people with ROS1-positive,..
08/15Genentech Receives FDA Accelerated Approval for Cancer Treatment
08/15ROCHE : FDA Approves Genentech's Rozlytrek (entrectinib) for People With ROS1-Po..
08/12NOVARTIS : Sandoz to Appeal Erelzi Patent Case in US
08/08Bayer buys BlueRock in $600 million bet on stem cell therapies
08/05ROCHE : Andrew Plank appointed President and General Manager of Roche Diagnostic..
08/05Roche's Tecentriq plus platinum-based chemotherapy reduced the risk of diseas..
08/05GENENTECH : 's Tecentriq® (ATEZOLIZUMAB) Plus Platinum-based Chemotherapy Reduce..
08/01Blue-blooded crabs at heart of pharma dispute on drug testing
07/31SPARK THERAPEUTICS : Roche, Spark extend $4.3 billion takeover again, this time ..
More news
Financials (CHF)
Sales 2019 61 050 M
EBIT 2019 21 615 M
Net income 2019 14 389 M
Debt 2019 3 426 M
Yield 2019 3,30%
P/E ratio 2019 17,0x
P/E ratio 2020 16,4x
EV / Sales2019 3,90x
EV / Sales2020 3,73x
Capitalization 235 B
Duration : Period :
Roche Holding Ltd. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ROCHE HOLDING LTD.
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 24
Average target price 294,77  CHF
Last Close Price 274,70  CHF
Spread / Highest target 29,6%
Spread / Average Target 7,31%
Spread / Lowest Target -27,2%
EPS Revisions
Severin Schwan Chief Executive Officer & Executive Director
Christoph Franz Chairman
Alan Hippe Chief Financial & Information Technology Officer
John Irving Bell Non-Executive Director
Andreas Oeri Independent Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
ROCHE HOLDING LTD.12.24%238 299
JOHNSON & JOHNSON1.79%346 681
MERCK AND COMPANY11.32%217 785
NOVARTIS17.81%204 677
PFIZER-20.62%191 651
NOVO NORDISK AS16.65%122 509